Skip to main content
Download PDF

Atherosclerosis is associated with plasma Aβ levels in non-hypertension patients

BMC Neurology volume 24, Article number: 218 (2024) Cite this article

Abstract

Background

Growing evidence indicated that to develop of atherosclerosis observed more often by people with Alzheimer’s disease (AD), but the underlying mechanism is not fully clarified. Considering that amyloid-β (Aβ) deposition in the brain is the key pathophysiology of AD and plasma Aβ is closely relate to Aβ deposition in the brain, in the present study, we investigated the relationships between atherosclerosis and plasma Aβ levels.

Methods

This was a population based cross-sectional study. Patients with high risk of atherosclerosis from Qubao Village, Xi’an were underwent carotid ultrasound for assessment of atherosclerosis. Venous blood was collected on empty stomach in the morning and plasma Aβ1−40 and Aβ1−42 levels were measured using ELISA. Multivariate logistic regression analysis was performed to investigate the relationships between carotid atherosclerosis (CAS) and plasma Aβ levels.

Results

Among 344 patients with high risk of atherosclerosis, 251(73.0%) had CAS. In the univariate analysis, the plasma Aβ levels had no significant differences between CAS group and non-CAS group (Aβ1−40: 53.07 ± 9.24 pg/ml vs. 51.67 ± 9.11pg/ml, p = 0.211; Aβ1−42: 40.10 ± 5.57 pg/ml vs. 40.70 pg/ml ± 6.37pg/ml, p = 0.285). Multivariate logistic analysis showed that plasma Aβ levels were not associated with CAS (Aβ1−40: OR = 1.019, 95%CI: 0.985–1.054, p = 0.270;Aβ1−42: OR = 1.028, 95%CI: 0.980–1.079, p = 0.256) in the total study population. After stratified by hypertension, CAS was associated with plasma Aβ1−40 positively (OR = 1.063, 95%CI: 1.007–1.122, p = 0.028) in the non-hypertension group, but not in hypertensive group. When the plasma Aβ concentrations were classified into four groups according to its quartile, the highest level of plasma Aβ1−40 group was associated with CAS significantly (OR = 4.465, 95%CI: 1.024–19.474, p = 0.046).

Conclusion

Among patients with high risk of atherosclerosis, CAS was associated with higher plasma Aβ1−40 level in non-hypertension group, but not in hypertension group. These indicated that atherosclerosis is associated with plasma Aβ level, but the relationship may be confounded by hypertension.

Peer Review reports

Introduction

Alzheimer’s disease (AD) is the most common cause of dementia, affecting more than 47 million people worldwide [1]. Amyloid-β (Aβ) deposition in the brain is the key pathological characteristic of AD, and the amyloid cascade hypothesis is the main pathogenesis of AD [2]. Compare to Aβ1−42 deposition in the brain mainly, Aβ1−40 deposits are mainly found in the brain and cerebral blood vessels, causing neurovascular dysfunction [3]. Aβ accumulation in the brain mainly come from the imbalance of Aβ production and clearance [4]. Aβ is generated from the cleavage of amyloid precursor protein (APP) by sequential β- and γ- secretases [5]. Aβ can be cleared from the brain into the peripheral blood through the blood-brain barrier (BBB) by LRP-1 protein, while reverse transport of peripheral Aβ across the BBB into the brain is depend on RAGE protein [6]. There is a complex dynamic equilibrium between Aβ burden in the brain and plasma Aβ [4]. Studies have shown that Aβ in the plasma is closely related to Aβ deposition in the brain [4, 5, 7].

Atherosclerosis is an important risk factor for ischemic stroke. Growing evidence have indicated that atherosclerosis is also associated with AD [8, 9]. Atherosclerosis could disrupt the structure and function of cerebrovascular, and induce hypoperfusion and hypoxia, which may promote the production of Aβ in the brain [10]. Meanwhile Aβ may contribute to ischemic brain even to atherosclerotic lesions through vascular oxidative stress and endothelial dysfunction [11]. However, the relationships between atherosclerosis and AD is not determined fully.

Carotid atherosclerosis (CAS) is a hallmark for atherosclerosis [12] and is closely associated with ischemic stroke [13, 14]. A large body of evidence suggested that CAS is associated with cognitive decline [15,16,17,18] as the patients with AD. In the present study, we investigated the relationships between CAS and plasma Aβ in patients with high-risk atherosclerosis.

Methods

Participants

This was a population based cross-sectional study. All participants came from Qubao village, Huyi district of Xi’an. The village was selected using clustering sampling method. The inclusion criteria was follow: (1) permanent resident who living in the village for more than 3 years; (2) aged 40 years or older (3)People who have at least 3 risk factors in the follow 8 items: smoking, less exercise, hypertension, diabetes, atrial fibrillation, hyperlipidemia, stroke family history and obesity. (4) Agree to participate in the study and signed written informed consent. Exclusion criteria: (1) Did not complete carotid ultrasound; (2) Missing data of plasma Aβ or outliers of plasma Aβ.;(3) With liver and kidney dysfunction. This study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiao tong University (No. XJTU1AF2014LSK-111).

Data collection

All participants received a face-to-face interview to complete a standardized questionnaires for general information (age, sex, education levels and jobs) and lifestyle habits (alcohol abuse, smoking history, physical activity level, sleep), the medical history (hypertension, diabetes, hyperlipidaemia, cardiovascular disease, transient ischaemic attack, stroke), and underwent a systemic and neurologic examination to measure height, weight, blood pressure and the pulse rate. Body mass index (BMI) was defined as a person’s weight in kilograms divided by the square of his or her height in meters (kg/m2). The questionnaire used in study was developed for a sequential design to determine the potential vascular factors for AD in the general population [19].

After fasting overnight, 3 ml cubital venous blood were collected from all subjects between 8 and 10 am, and placed in an EDTA anticoagulant tube, centrifuged at 3000 g for 10 min at room temperature (20℃), and had the supernatant plasma extracted and aliquoted. Aliquots of plasma were stored at -80℃ pending biochemical analyses. Laboratory test parameters were measured in the clinical laboratory of the First Affiliated Hospital of Xi’an Jiaotong University.

Atherosclerosis assessment

High-resolution B-mode ultrasonography with a linear-array, 5 to 10 MHz transducer was used to assess CAS. The probe scanned the proximal, middle and distal common carotid arteries, the carotid sinus, internal carotid artery, external carotid artery, and measured carotid artery, internal carotid artery, external carotid artery diameter, intima-media thickness (IMT). IMT is the distance between the lumen membrane interface and the media-adventitia interface. The diagnosis of CAS is: (1) IMT ≥ 1.0 mm. (2) Had a plaque in carotid artery, including common carotid arteries, carotid sinus, internal carotid artery, external carotid artery.

Quantification of plasma Aβ

The levels of plasma Aβ1−40 and Aβ1−42 were measured as previously described [20]. Briefly, double-antibody sandwich enzyme-linked immunoassay (ELISA) was used to determine plasma Aβ concentrations. The kit was purchased from Shanghai Yuanye Biotechnology Co., Ltd. All samples were measured in duplicate using an RT-6000 analyzer from Rayto Co. based in Shenzhen, China. The measurements were taken at a wavelength of 450 nm, and the procedures followed were strictly in accordance with the instructions provided. The concentration was calculated based on the standard curve, and the average was taken as the sample concentration.

Definition of covariates

The diseases involved in this study are defined as previously described [21].Hypertension was defined as follows: a mean systolic blood pressure measurement ≥ 140mmHg or a diastolic blood pressure ≥ 90mmHg, self-reported medical diagnosis, or the usage of antihypertensive drugs. The definition of diabetes mellitus included the following criteria: fasting blood glucose (FBG) ≥ 7.0mmol/L, the usage of diabetic medication or insulin. The definition of hyperlipidaemia included the following criteria: serum cholesterol concentration (TC) > 5.18 mol/L, serum triglyceride concentration (TG) > 1.70 mmol/L, low density lipoprotein cholesterol (LDL-c) > 3.37 mmol/L, high density lipoprotein cholesterol (HDL-c) < 1.04 mmol/L, self-reported medical diagnosis, or the usage of lipid-lowering drugs.

Statistical analyses

SPSS version 24.0 (SPSS Inc., IBM, Chicago) was used to perform statistical analyses. Continuous variables with approximately normal distribution were expressed as means ± standard deviations (SDs). The data of skewed distributions were described as the median (25% percentile, 75% percentile). Percentages were used for categorical variables. p < 0.05 was identified as a significant difference.

For univariate analyses, one-way analysis of variance, unpaired Student’s t-test, Mann-Whitney U test, and χ2test (the chi-squared test) were chosen to compare the different types of variables. About one-way analysis of variance test, homogeneity of variances of the variables was confirmed with Levene’s test, and the comparison between any two groups was performed with least significant difference test. Then, for multivariate analysis, multiple linear regression (MLR) analysis was used to analyze the relationship between CAS and plasma Aβ1−40, Aβ1−42, Aβ1−42/Aβ1−40 levels. In the MLR models, Aβ1−40, Aβ1−42 concentrations were the dependent variables, respectively. Other covariates were independent variables, adjusted factors including age, sex, BMI, medical history of stroke, diabetes, coronary heart disease, dyslipidemia, lack of exercise, smoking, and drinking, FBG, TG, TC, LDL-c, HDL-c.

Results

Demographics and clinical characteristics

There were 2060 in the population, among which 820 patients met the criteria for high risk of atherosclerosis, 364 did not complete carotid ultrasonography, 97 did not have plasma Aβ, 15 had outliers of Aβ levels, finally 344 patients included in the analysis. (Fig. 1)

Fig. 1
figure 1

The enrollment flow chart of this study

Full size image

Among 344 participants, 251(73.0%) had CAS. Compare to non-CAS group, CAS group was older (61.54 ± 9.01 years vs. 51.05 ± 7.03 years, p<0.0001), and had more hypertension (60.6% vs. 47.3%, p = 0.028), diabetes mellitus (32.3% vs. 16.1%, p = 0.003), stroke (35.5% vs. 15.1%, p<0.0001) and less dyslipidemia (70.1% vs. 81.7%, p = 0.031). CAS group had lower BMI (26.84 ± 3.03 vs. 27.81 ± 3.08, p = 0.009) and higher HDL-c (1.37 ± 0.33 vs. 1.28 ± 0.28, p = 0.032), while others had no significant difference between the two groups. (Table 1)

Table 1 Demographic data and clinical characteristics of the study population
Full size table

Comparison of plasma Aβ levels between CAS group and non-CAS group

As shown in Table 1, the level of plasma Aβ1−40 and Aβ1−42 had no differences between CAS group and non-CAS group (Aβ1−40: 53.07 ± 9.24 pg/ml vs. 51.67 ± 9.11 pg/ml, p = 0.211; Aβ1−42: 40.09 ± 5.57 pg/ml vs. 40.10 ± 5.57 pg/ml, p = 0.285). Also, the Aβ1−40/Aβ1−42 ratio had no differences between CAS group and non-CAS group (1.33 ± 0.34 vs. 1.32 ± 0.32, p = 0.642).

The relationships between CAS and plasma Aβ in total study population

To investigate the relationships between CAS and plasma Aβ levels, a multiple linear regression analysis was used, as plasma Aβ levels as the dependent variable, and CAS as covariates. As shown in Table 2, plasma Aβ1–40 was not related with CAS in unadjusted MLR model, and in MLR model adjusted for age, sex, BMI, medical history of stroke, diabetes, coronary heart disease, dyslipidemia, lack of exercise, smoking, and drinking, FBG, TG, TC, LDL-c, HDL-c. Also. plasma Aβ1–42 was not associated with CAS in unadjusted MLR model and adjusted MLR model.

Table 2 Multiple linear regression analysis of Aβ and CAS in total study population
Full size table

Comparison between hypertension group and no-hypertension

As hypertension is an important risk factor for atherosclerosis, and also is associated with plasma Aβ levels, we stratified the participants into hypertension group (n = 196) and non- hypertension (n = 148). As shown in Table 3, compared to non-hypertension group, hypertension group are older, had more females, diabetes mellitus, cardiovascular disease and stroke, CAS, drinking, BMI. The levels of plasma Aβ1−40 and Aβ1−42 had no significant differences between hypertension group and non-hypertension group.

Table 3 General characteristics of the total study population
Full size table

After stratified by hypertension, in the non-hypertension group, plasma Aβ1−42 was higher in CAS group than that in non-CAS group (41.50 ± 7.01 pg/ml vs. 39.42 ± 5.18 pg/ml, p = 0.012), but plasma Aβ1−40 had no significant differences between CAS group and non-CAS group (53.53 ± 9.49 pg/ml vs. 50.67 ± 8.79 pg/ml, p = 0.391). In the hypertension group, both plasma Aβ1−40 and Aβ1−42 had no difference between CAS group and non-CAS group. (Table 4)

The Aβ1–40 (53.11 ± 8.91 pg/ml vs. 50.25 ± 10.38 pg/ml, p = 0.088) and Aβ1–42(40.78 ± 6.60 pg/ml vs. 40.93 ± 6.34 pg/ml, p = 0.351) levels had no significant difference between non-stroke group and stroke groups in the non-hypertensive group. Also, in the non-hypertensive group, the Aβ1–40 (52.07 ± 9.40 pg/ml vs. 54.42 ± 8.52 pg/ml, p = 0.112) and Aβ1–42(40.92 ± 6.06 pg/ml vs. 40.04 ± 6.63 pg/ml, p = 0.351) levels had no significant difference between non-stroke group and stroke group.

Table 4 Plasma levels of Aβ1–40 and Aβ1–42 in total study population
Full size table

Multivariate logistic regression analysis of plasma Aβ and CAS after stratified by hypertension

To exclude the effects of covariates on the relationships between CAS and plasma Aβ levels, a multivariate logistic analysis stratified by hypertension was used. CAS is as the dependent variable (yes or no), and plasma Aβ levels (Aβ1−40, Aβ1−42) and covariates are as independent variables to establish a logistic regression model. Covariates were chosen according to previously described in univariate analyses as well as covariates reported to be related to cognition in previous studies.

In the non-hypertension group, plasma Aβ1–40 did not associate with CAS in unadjusted MLR model, but significantly associate with CAS in MLR Models adjusted for all covariates which include age, sex, BMI, medical history of stroke, diabetes, coronary heart disease, dyslipidemia, lack of exercise, smoking, and drinking, FBG, TG, TC, LDL-c, HDL-c.(OR = 1.063, 95%CI: 1.007–1.122, p = 0.028). (Table 5）However, plasma Aβ1–42 did not associate with CAS in MLR models whenever they are unadjusted or adjusted for covariates.

In the hypertension group, both plasma Aβ1–40 and Aβ1–42 were not associated with CAS in unadjusted Models and adjusted Models for all covariates. (Table 6)

Table 5 Logistic regression analysis of plasma Aβ and CAS in non-hypertension group
Full size table
Table 6 Logistic regression analysis of plasma Aβ and CAS in hypertension group
Full size table

According to plasma Aβ concentrations, non-hypertension group were classified into four quartiles. Multivariate logistic regression analysis showed that the Quartile 1 (the lowest level of the plasma Aβ1−40) group as the reference, the Quartile 4 (the highest level of plasma Aβ1−40) group was obviously associated with CAS (OR = 4.465, 95%CI: 1.024–19.474, p = 0.046), but plasma Aβ1−42 did not. (Table 7)

Table 7 Multivariate Logistic Regression Analysis of CAS and Different Levels of Plasma Aβ
Full size table

Discussion

In this population based cross-sectional study, we found that plasma Aβ levels had no significant difference between CAS group and non-CAS group in the population with high risk of atherosclerosis. However, in the stratified multiple analyses, we found that CAS was associated with higher plasma Aβ1−40 level in non-hypertension group, but not in hypertension group.

The relationship between atherosclerosis and AD has not been determined. Due to plasma Aβ closely relate to Aβ deposition in the brain, several studies have explored the relationships between atherosclerosis and plasma Aβ. One study found that Aβ1−40 deposits in CAS plaques and in the aorta [22]. Subclinical atherosclerosis patients and CAD-stabilized patients have higher levels of circulating Aβ1−40, which predict cardiovascular mortality and major adverse cardiac events [23]. Cohort study showed that plasma Aβ1−40 level was significantly associated with arterial stiffness progression, subclinical atherosclerotic events, and coronary heart disease events [24]. In the present study, we used a cluster sampling method to select study population and all people who living in the village were included in the analysis. To make sure the enough individuals with atherosclerosis for analyses, we enrolled the patients with high risk of atherosclerosis. As CAS is easily and exactly detected using B-mode ultrasonography, and is closely relate to ischemic stroke, so we detected CAS to indicating atherosclerosis. The results showed that the prevalence of CAS was 73.0% in our study group.

It is known that hypertension is the most important risk factor for atherosclerosis. In the previous study, we found that elevated blood pressure was associated with increased plasma Aβ1-40 level in middle-aged and elderly [25]. So, we did stratified analysis by hypertension, and found that CAS group had higher plasma Aβ1-40 level in non-hypertension group. The results were demonstrated in the multiple analyses after adjusted for covariates. These suggested that the association between CAS and plasma Aβ1-40 level was confounded by hypertension.

The reason of CAS relate to plasma Aβ level have not been clarified fully. Many animal and cell studies have shown that Aβ1−40 is involved in the formation of atherosclerosis through various channels. Knockout of Herpud1 reduced Aβ1−40 expression other than lipid metabolism and alleviated atherosclerosis via JNK/AP1 signaling inhibition [26]. Neuronal overexpression of Aβ in atherosclerotic mice predisposes to macrophage activation and endothelial dysfunction, which promotes atherosclerosis [27]. Li found a positive correlation between brain Aβ loading and aortic fat streak formation, and suggested that local Aβ overexpression in the brain maintains the inflammatory response and progression of atherosclerosis in mouse models by developing endothelial dysfunction and atherosclerosis [28]. Puglielli suggests that Aβ-catalyzed the formation of 4-chosterane-3-ketones may be responsible for the increase in atherosclerosis in Tg2576 transgenic mice [29]. In contrast, experimental study [30] have shown that spatial memory was significantly affected 3 weeks after calcification using a mouse model based on carotid artery calcification. Carotid artery stiffness did not affect the production of Aβ or tau phosphorylation in mice, but resulted in a modest increase in the proportion of Aβ1−40/Aβ1−42 in the frontal cortex.

In the Rotterdam study [31], they found that patients with severe atherosclerosis had higher risk for AD compared with patients without atherosclerosis. A systematic review showed that [32], peripheral arterial disease was associated with dementia and cognitive impairment. The carotid artery stenosis had a higher risk for dementia and for cognitive impairment. These all suggest that atherosclerosis may play a role in the progression of dementia, the underlying mechanism may associate with the effects of plasma Aβ on carotid atherosclerosis.

Atherosclerotic vascular disease and AD have a common pathophysiological involved in inflammation, macrophage infiltration, and vascular obstruction despite their different end-stage manifestations [33]. Study has shown that [34] atherosclerotic lesions in the elderly contain a heterogeneous mixture of Aβ peptides. The source of these Aβ peptides may be vascular wall cells expressing APP/PN2/Aβ, as well as platelets involved in atherosclerotic inflammation and perturbation coagulation cascades. De Meyer and colleagues clearly showed the presence of APP and Aβ in platelets engulfed by macrophages in the neo vascular-forming region of advanced atherosclerotic lesions [35]. The presence of Aβ peptides stimulated by iNOS and COX-2 production, increase activation of macrophages and sustain synthesis of pro-inflammatory-related factors. Aβ accumulation induces microvascular inflammation mediated by cytokines and chemokines that act on neurons, glial, endothelial cells, and muscle cells [36, 37]. These microvascular inflammations eventually lead to the destruction of the vascular walls. The presence of Aβ peptides in atherosclerotic plaques may synergistically increase the chronic inflammatory process that maintains degeneration and destruction of the arterial wall.

CAS associated with plasma Aβ1−40 in the non-hypertensive group, but not hypertension group, suggesting that the relationship between Aβ1−40 and CAS was confused by blood pressure. Hypertension is a common risk factor for stroke and AD [38, 39]. Hypertension has been shown to worsen Aβ-induced neurovascular dysfunction and promote β secretase activity, these lead to an increase in Aβ production, which may contribute to pathogenic interactions between hypertension, stroke and AD [40]. Hypertension is associated with cognitive impairment and pathological features of AD, including nerve fiber tangles and Aβ deposition [41]. Our previous study found that the increase in PP is associated with an increase in plasma Aβ1−40 and a decrease in the soluble advanced glycation end product-specific receptor (sRAGE), as well as an increase in blood pressure associated with an increase in plasma Aβ1−40 levels in middle-aged and elderly ApoEε4 non-carriers. Its underlying mechanism may be related to peripheral Aβ clearance. In addition, under normal blood pressure, the walls of the blood vessels are not damaged, and the transport of Aβ is not restricted. However, in hypertension, blood vessels may be damaged, so the transport of Aβ peptides worsens. Thus, in the normal blood pressure group was able to more realistically reflect the relationship between plasma Aβ and CAS.

There were several limitations should be noted. First, this is a population based cross-sectional study, we did not follow-up the changes of plasma Aβ, and did determine the cause relationship between CAS and plasma Aβ. Second, due to smaller sample size, we did not analyze the relationships between CAS degree and plasma Aβ levels. We are not sure whether sever CAS has more changes of plasma Aβ level. Third, the deposition of Aβ in the brain has not been simultaneously detected.

Conclusions

In summary, through this population based cross-sectional study, we found that in patients with higher risk of atherosclerosis., CAS was associated with higher plasma Aβ1−40 level in non-hypertension group but not in hypertension group. These indicated that atherosclerosis was associated with plasma Aβ level, but the relationship may be confounded by hypertension.

Data availability

No datasets were generated or analysed during the current study.

References

  1. Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, et al. Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: update and areas of immediate need. Alzheimers Dement. 2019;15 2:292–312. https://doi.org/10.1016/j.jalz.2018.09.009.

    Article  Google Scholar 

  2. Hanseeuw BJ, Betensky RA, Jacobs HIL. Association of Amyloid and tau with cognition in preclinical Alzheimer Disease: a longitudinal study (vol, pg, 2019). Jama Neurol. 2019;76 8:986. https://doi.org/10.1001/jamaneurol.2019.2144.

    Article  Google Scholar 

  3. Apatiga-Perez R, Soto-Rojas LO, Campa-Cordoba BB, Luna-Viramontes NI, Cuevas E, Villanueva-Fierro I, et al. Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer’s disease. Metab Brain Dis. 2022;37 1:39–50. https://doi.org/10.1007/s11011-021-00814-4.

    Article  CAS  Google Scholar 

  4. Zuroff L, Daley D, Black KL, Koronyo-Hamaoui M. Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes. Cell Mol Life Sci. 2017;74 12:2167–201. https://doi.org/10.1007/s00018-017-2463-7.

    Article  CAS  Google Scholar 

  5. DeMattos RB, Bales KR, Parsadanian M, O’Dell MA, Foss EM, Paul SM, et al. Plaque-associated disruption of CSF and plasma amyloid-beta (abeta) equilibrium in a mouse model of Alzheimer’s disease. J Neurochem. 2002;81:2229–36.

    Article  Google Scholar 

  6. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miller MC, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 2006;112(4):405–15.

    Article  CAS  PubMed  Google Scholar 

  7. Cho SM, Lee S, Yang S-H, Kim HY, Lee MJ, Kim HV, et al. Age-dependent inverse correlations in CSF and plasma amyloid-β(1–42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice. Sci Rep. 2016;6:20185. https://doi.org/10.1038/srep20185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Waziry R, Claus JJ, Hofman A. Dementia risk following ischemic stroke: a systematic review and Meta-analysis of factors collected at Time of Stroke diagnosis. J Alzheimers Disease. 2022;90 4:1535–46. https://doi.org/10.3233/Jad-220317.

    Article  Google Scholar 

  9. Lathe R, Sapronova A, Kotelevtsev Y. Atherosclerosis and Alzheimer–diseases with a common cause? Inflammation, oxysterols, vasculature. BMC Geriatr. 2014;14:36. https://doi.org/10.1186/1471-2318-14-36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Duong MT, Nasrallah IM, Wolk DA, Chang CCY, Chang TY. Cholesterol, atherosclerosis, and APOE in Vascular contributions to cognitive impairment and dementia (VCID): potential mechanisms and therapy. Front Aging Neurosci. 2021;13:647990. https://doi.org/10.3389/fnagi.2021.647990.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18 7:419–34. https://doi.org/10.1038/nrn.2017.48.

    Article  CAS  Google Scholar 

  12. Kapasi A, Schneider JA. Vascular contributions to cognitive impairment, clinical Alzheimer’s disease, and dementia in older persons. Biochim Biophys Acta. 2016;1862 5:878–86. https://doi.org/10.1016/j.bbadis.2015.12.023.

    Article  CAS  Google Scholar 

  13. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/american stroke association. Stroke. 2011;42 9:2672–713. https://doi.org/10.1161/STR.0b013e3182299496.

    Article  Google Scholar 

  14. Meyer ML, Palta P, Tanaka H, Deal JA, Wright J, Knopman DS, et al. Association of Central Arterial Stiffness and pressure pulsatility with mild cognitive impairment and dementia: the atherosclerosis risk in communities Study-Neurocognitive Study (ARIC-NCS). J Alzheimers Dis. 2017;57 1:195–204. https://doi.org/10.3233/JAD-161041.

    Article  Google Scholar 

  15. Cai YR, Hausdorff JM, Bean JF, Manor B, You TJ, Leveille SG. Participation in cognitive activities is associated with foot reaction time and gait speed in older adults. Aging Clin Exp Res. 2021;33 12:3191–8. https://doi.org/10.1007/s40520-020-01583-3.

    Article  Google Scholar 

  16. Akioka N, Takaiwa A, Kashiwazaki D, Kuwayama N, Endo S, Kuroda S. Clinical significance of hemodynamic cerebral ischemia on cognitive function in carotid artery stenosis: a prospective study before and after revascularization. Q J Nucl Med Mol Im. 2017;61 3:323–30. https://doi.org/10.23736/S1824-4785.17.02781-9.

    Article  Google Scholar 

  17. Vibha D, Prasad K, Dwivedi SN, Kant S, Pandit AK, Tiemeier H, et al. Carotid intima-media thickness (cIMT) and Cognitive Performance A Population-based cross-sectional study from North India. Alz Dis Assoc Dis. 2023;37(1):35–41. https://doi.org/10.1097/Wad.0000000000000542.

    Article  CAS  Google Scholar 

  18. Viticchi G, Falsetti L, Potente E, Bartolini M, Silvestrini M. Impact of carotid stenosis on cerebral hemodynamic failure and cognitive impairment progression: a narrative review. Ann Transl Med. 2021;9 14; doi: ARTN 120921037/atm-20-7226

  19. Jiang Y, Shang S, Li P, Chen C, Dang L, Wang J, et al. Pulse pressure is associated with plasma amyloid-β transport dysfunction. J Hypertens. 2018;36 3:569–79. https://doi.org/10.1097/HJH.0000000000001565.

    Article  CAS  Google Scholar 

  20. Wei M, Zhao BY, Huo K, Deng YN, Shang SH, Liu J, et al. Sleep Deprivation Induced plasma Amyloid-β transport disturbance in healthy young adults. J Alzheimers Disease. 2017;57 3:899–906. https://doi.org/10.3233/Jad-161213.

    Article  Google Scholar 

  21. Hu N, Gao L, Jiang Y, Wei S, Shang S, Chen C, et al. The relationship between blood lipids and plasma amyloid beta is depend on blood pressure: a population-based cross-sectional study. Lipids Health Dis. 2020;19(1:8). https://doi.org/10.1186/s12944-020-1191-4.

  22. Bu G, Cam J, Zerbinatti C. LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci. 2006;1086:35–53.

    Article  CAS  PubMed  Google Scholar 

  23. Stamatelopoulos K, Mueller-Hennessen M, Georgiopoulos G, Sachse M, Boeddinghaus J, Sopova K, et al. Amyloid-beta (1–40) and mortality in patients with Non-ST-Segment elevation Acute Coronary Syndrome: a Cohort Study. Ann Intern Med. 2018;168 12:855–65. https://doi.org/10.7326/M17-1540.

    Article  Google Scholar 

  24. Stamatelopoulos K, Sibbing D, Rallidis LS, Georgiopoulos G, Stakos D, Braun S, et al. Amyloid-beta (1–40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol. 2015;65 9:904–16. https://doi.org/10.1016/j.jacc.2014.12.035.

    Article  CAS  Google Scholar 

  25. Jiang Y, Shang SH, Li P, Chen C, Dang L, Wang JJ, et al. Pulse pressure is associated with plasma amyloid-β transport dysfunction. J Hypertens. 2018;36 3:569–79. https://doi.org/10.1097/Hjh.0000000000001565.

    Article  Google Scholar 

  26. Gao F, Zhang J, Ni T, Lin N, Lin H, Luo H, et al. Herpud1 deficiency could reduce amyloid-beta40 expression and thereby suppress homocysteine-induced atherosclerosis by blocking the JNK/AP1 pathway. J Physiol Biochem. 2020;76 3:383–91. https://doi.org/10.1007/s13105-020-00741-5.

    Article  CAS  Google Scholar 

  27. Tibolla G, Norata GD, Meda C, Arnaboldi L, Uboldi P, Piazza F, et al. Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. Atherosclerosis. 2010;210 1:78–87. https://doi.org/10.1016/j.atherosclerosis.2009.10.040.

    Article  CAS  Google Scholar 

  28. Li L, Cao D, Garber DW, Kim H, Fukuchi K-i. Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer’s disease. Am J Pathol. 2003;163 6:2155–64.

    Article  Google Scholar 

  29. Puglielli L, Friedlich AL, Setchell KDR, Nagano S, Opazo C, Cherny RA, et al. Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest. 2005;115 9:2556–63.

    Article  Google Scholar 

  30. Muhire G, Iulita MF, Vallerand D, Youwakim J, Gratuze M, Petry FR, et al. Arterial stiffness due to carotid calcification disrupts cerebral blood Flow Regulation and leads to cognitive deficits. J Am Heart Assoc. 2019;8 9:e011630. https://doi.org/10.1161/JAHA.118.011630.

    Article  Google Scholar 

  31. Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet. 1997;349 9046:151–4. https://doi.org/10.1016/s0140-6736(96)09328-2.

    Article  Google Scholar 

  32. Yang Z, Wang H, Edwards D, Ding C, Yan L, Brayne C, et al. Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: a systematic review and meta-analysis. Ageing Res Rev. 2020;57:100962. https://doi.org/10.1016/j.arr.2019.100962.

    Article  CAS  PubMed  Google Scholar 

  33. Liao J, Chen G, Liu X, Wei ZZ, Yu SP, Chen Q, et al. C/EBPbeta/AEP signaling couples atherosclerosis to the pathogenesis of Alzheimer’s disease. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01556-0.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kokjohn TA, Van Vickle GD, Maarouf CL, Kalback WM, Hunter JM, Daugs ID, et al. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta. 2011;1812 11:1508–14. https://doi.org/10.1016/j.bbadis.2011.07.004.

    Article  CAS  Google Scholar 

  35. De Meyer GRY, De Cleen DMM, Cooper S, Knaapen MWM, Jans DM, Martinet W, et al. Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res. 2002;90:111197–204.

    Article  Google Scholar 

  36. Townsend KP, Obregon D, Quadros A, Patel N, Volmar C, Paris D, et al. Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Ann N Y Acad Sci. 2002;977:65–76.

    Article  CAS  PubMed  Google Scholar 

  37. Rozemuller AJM, van Gool WA, Eikelenboom P. The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer’s disease: therapeutic implications. Curr Drug Targets CNS Neurol Disord. 2005;4(3):223–33.

    Article  CAS  PubMed  Google Scholar 

  38. O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388 10046:761–75. https://doi.org/10.1016/S0140-6736(16)30506-2.

    Article  Google Scholar 

  39. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10 9:819–28. https://doi.org/10.1016/S1474-4422(11)70072-2.

    Article  Google Scholar 

  40. Faraco G, Park L, Zhou P, Luo W, Paul SM, Anrather J, et al. Hypertension enhances Aβ-induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP. J Cereb Blood Flow Metab. 2016;36:1241–52.

    Article  Google Scholar 

  41. Carnevale D, Mascio G, D’Andrea I, Fardella V, Bell RD, Branchi I, et al. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension. 2012;60(1):188–97. https://doi.org/10.1161/HYPERTENSIONAHA.112.195511.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors were thankful for the cooperation of all participants in our study.

Funding

This work was supported by the Scientific and technological innovation 2030 (No. 2021ZD0201808).

Author information

Author notes

  1. Chen Chen and Wang Anqi contributed equally to this work.

Authors and Affiliations

  1. Department of Neurology, The First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Rd, Xi’an, 710061, China

    Chen Chen, Wang Anqi, Gao Ling, Wei Shan, Dang Liangjun, Shang Suhang, Huo Kang, Qu Qiumin & Wang Jin

  2. Clinical research center, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

    Gao Fan

  3. Huyi Hospital of Traditional Chinese Medicine, Xi’an, China

    Wang Jingyi

Authors
  1. Chen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wang Anqi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gao Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dang Liangjun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shang Suhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Huo Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gao Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wang Jingyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Qu Qiumin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wang Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Chen Chen and Wang Anqi collected information, performed the statistical analysis and wrote the manuscript. Gao Ling, Wei Shan, Dang Liangjun, Shang Suhang, Huo Kang, Wang Jingyi collected the data. Gao Fan participated in the statistical analysis. Wang Jin and Qu Qiumin developed the idea, provided technical guidance and made revisions.

Corresponding authors

Correspondence to Qu Qiumin or Wang Jin.

Ethics declarations

Ethics approval and consent to participate

A favourable ethical opinion for this study was received from The First Affiliated Hospital of Xi’an Jiaotong University Research Ethics Committee (Reference: XJTU2014-111). Before the enrollment, written informed consent will be obtained from patients, or from the caregivers. In accordance with the Declaration of Helsinki, All methods were conducted in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, C., Anqi, W., Ling, G. et al. Atherosclerosis is associated with plasma Aβ levels in non-hypertension patients. BMC Neurol 24, 218 (2024). https://doi.org/10.1186/s12883-024-03722-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12883-024-03722-z

Keywords

BMC Neurology

ISSN: 1471-2377

Contact us